2019
DOI: 10.1016/j.mce.2019.01.023
|View full text |Cite
|
Sign up to set email alerts
|

Modulation of nuclear receptor function: Targeting the protein-DNA interface

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0
1

Year Published

2019
2019
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 19 publications
(8 citation statements)
references
References 116 publications
0
7
0
1
Order By: Relevance
“…NRs are a superfamily of ligand-dependent transcriptional factors containing n N-terminal transactivation domain, a flexible hinge region, and a C-terminal ligand-binding domain (LBD) [6,8,13]. NRs are classified mainly into two types according to their subcellular distribution in the absence of a ligand and their mechanisms: Type I steroid receptors, including the estrogen receptor (ER), androgen receptor (AR), progesterone receptor (PR), and glucocorticoid receptor (GR); and Type II nonsteroid receptors, including the thyroid receptor (TR alpha and beta), retinoic acid receptor (RAR alpha, beta, and gamma), retinoid X receptor (RXR), vitamin D receptor (VDR), peroxisome proliferator-activated receptor (PPAR alpha, beta, and gamma), liver X receptor (LXR), farnesoid X receptor (FXR), and pregane X receptor (PXR), [6,14,15]. In the absence of a ligand, the type I NR forms inactive complexes with chaperone proteins in the cytoplasm, whereas type II NR, regardless of the ligand-binding status, is located in the nucleus and binds to the DNA response elements of its target genes along with corepressors [6,14,16].…”
Section: Introductionmentioning
confidence: 99%
“…NRs are a superfamily of ligand-dependent transcriptional factors containing n N-terminal transactivation domain, a flexible hinge region, and a C-terminal ligand-binding domain (LBD) [6,8,13]. NRs are classified mainly into two types according to their subcellular distribution in the absence of a ligand and their mechanisms: Type I steroid receptors, including the estrogen receptor (ER), androgen receptor (AR), progesterone receptor (PR), and glucocorticoid receptor (GR); and Type II nonsteroid receptors, including the thyroid receptor (TR alpha and beta), retinoic acid receptor (RAR alpha, beta, and gamma), retinoid X receptor (RXR), vitamin D receptor (VDR), peroxisome proliferator-activated receptor (PPAR alpha, beta, and gamma), liver X receptor (LXR), farnesoid X receptor (FXR), and pregane X receptor (PXR), [6,14,15]. In the absence of a ligand, the type I NR forms inactive complexes with chaperone proteins in the cytoplasm, whereas type II NR, regardless of the ligand-binding status, is located in the nucleus and binds to the DNA response elements of its target genes along with corepressors [6,14,16].…”
Section: Introductionmentioning
confidence: 99%
“…However, at higher concentrations (≥5 µM), it inhibited proliferation in both cell lines [306]. The inhibition of proliferation was attributed to direct covalent modifications of Cys227 and Cys240 in the C-terminal Zinc fingers in the ERα DBD by 15d-PGJ2 and thus disruption of transcription of ER dependent genes [306,307].…”
Section: Compoundmentioning
confidence: 97%
“…In addition, only the ligand-binding domains (LBDs) of NRs were targeted in this study. However, it has been suggested that the DNA binding domains (DBDs) of NRs and even the DNA sites recognized by NRs can also be targeted by ligands (Brodie 2005;Meijsing et al 2009;Li et al 2014;Dalal et al 2014;Shizu et al 2018;Frank et al 2018;Pal et al 2019;Veras Ribeiro Filho et al 2019). Thus we expect that the application of our in silico method to these new molecular interfaces will also facilitate potential EDC prediction.…”
Section: Future Perspectivesmentioning
confidence: 99%